Diagnostic Imaging Market to Reach US$ 33.2 Bn by 2031, Growing at 4.6% CAGR: New Report by Wissen Research

The global diagnostic imaging market is projected to expand from $26.5 billion in 2026 to $33.2 billion by 2031, a 4.6% CAGR, driven by chronic disease demand, aging populations, and adoption of AI-enabled, portable, and cloud-based imaging. AI reconstruction, photon-counting CT, and teleradiology are improving throughput, image quality, and access, while Asia-Pacific is expected to be the fastest-growing region. Growth is constrained by Medicare reimbursement pressure, including a permanent 2.5% work-RVU reduction across roughly 7,700 diagnostic and procedural codes and payment cuts of up to 30.8% for certain combined head-and-neck CTA codes.

Analysis

The relevant investable shift is not broad imaging-market growth but mix: vendors that convert AI into measurable scanner utilization, service pull-through, and installed-base upgrades can outgrow capital-equipment budgets. GEHC is best positioned among the listed names because workflow software and deep-learning reconstruction can defend pricing by offering a hospital ROI case—more scans per unit and less labor per study—rather than relying on clinical novelty. SHL has the strongest high-end CT/interventional exposure, while PHG’s enterprise informatics footprint offers recurring-revenue protection if health systems defer large hardware purchases.

The reimbursement backdrop creates a barbell rather than a sector-wide positive. Lower reimbursement raises providers’ hurdle rate for premium-system replacement, favoring vendors with financing, service contracts, lower-cost upgrades, and productivity software; it penalizes imaging-center economics and potentially elongates modality replacement cycles over the next 6-18 months. This is also unfavorable to cash-burning disruptors NNOX and BFLY if adoption requires new purchasing budgets: clinical access narratives do not overcome procurement friction without evidence of reimbursement, utilization, and gross-margin improvement.

Near-term, this press-release-level market forecast is unlikely to alter estimates. The 1-3 month catalysts are GEHC and PHG order intake, book-to-bill, service revenue, and management commentary on North American hospital capex; the more consequential 6-18 month catalyst is whether AI produces enough throughput to offset reimbursement pressure. Consensus may be too focused on hardware AI differentiation: radiologist shortages make interoperability, workflow integration, cybersecurity, and installed-base conversion the actual monetization bottlenecks, favoring incumbents over standalone imaging challengers.

Falsify the GEHC/SHL relative thesis if order growth decelerates despite AI launches, backlog conversion weakens, or hospitals explicitly cite reimbursement-driven deferrals; a sustained deterioration in service margins would indicate that AI is being bundled rather than monetized. For BFLY/NNOX, quarterly paid subscriptions, recurring revenue, cash burn, and gross margin matter more than device placements or regulatory milestones.

Key Decisions for Investors

• Initiate a 3-6 month long GEHC / short BFLY pair, sized beta-neutral. GEHC has installed-base and service-revenue downside protection; BFLY remains more exposed to discretionary point-of-care purchasing and funding needs. Target 10-15% relative return; exit if GEHC organic orders miss expectations or BFLY demonstrates two consecutive quarters of accelerating recurring revenue with narrowing cash burn.
• Maintain SHL as the preferred European large-cap imaging exposure over PHG for a 6-12 month horizon where high-acuity CT and procedural workflow adoption persists; use PHG as the more defensive alternative if hospital capex indicators soften. Reassess after next reported order intake and margin guidance, not on market-growth reports.
• Avoid adding NNOX or BFLY solely on AI/portable-imaging narratives. Set an investable alert only after evidence of reimbursement-supported utilization and a funded path to at least 24 months of liquidity; absent that, dilution and procurement-cycle risk dominate the addressable-market upside.
• Monitor U.S. imaging reimbursement implementation and hospital capital-spending commentary over the next two quarters. A broader-than-expected reduction in replacement budgets would favor PHG’s informatics/service mix and argue for reducing GEHC/SHL hardware exposure.